Results From REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 03期
关键词：
ACUTE GVHD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：3
相关论文
共 50 条
  • [21] Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results
    Gonzalez Vicent, Martay
    Molina, Blanca
    Gonzalez de Pablo, Jesus
    Castillo, Ana
    Angel Diaz, Miguel
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : 319 - 326
  • [22] Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide
    Mayer, Jiri
    Krejci, Marta
    Pospisil, Zdenek
    Doubek, Michael
    Janikova, Andrea
    Zackova, Daniela
    Racil, Zdenek
    Smardova, Lenka
    Navratil, Milan
    Kamelander, Jan
    EXPERIMENTAL HEMATOLOGY, 2009, 37 (06) : 767 - 773
  • [23] Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
    Zeiser, Robert
    Polverelli, Nicola
    Ram, Ron
    Hashmi, Shahrukh K.
    Chakraverty, Ronjon
    Flowers, Mary E. D.
    Dawkins, Fitzroy
    Hollaender, Norbert
    Gowda, Maanasa
    Stefanelli, Tommaso
    Lee, Stephanie J.
    Teshima, Takanori
    Locatelli, Franco
    BLOOD, 2020, 136
  • [24] FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
    Przepiorka, Donna
    Luo, Lola
    Subramaniam, Sriram
    Qiu, Junshan
    Gudi, Ramadevi
    Cunningham, Lea C.
    Nie, Lei
    Leong, Ruby
    Ma, Lian
    Sheth, Christopher
    Deisseroth, Albert
    Goldberg, Kirsten B.
    Blumenthal, Gideon M.
    Pazdur, Richard
    ONCOLOGIST, 2020, 25 (02): : E328 - E334
  • [25] Treatment of steroid-refractory acute and chronic graft-versus-host disease with ruxolitinib in adults and children
    Moiseev, Ivan
    Morozova, Elena
    Barabanshikova, Maria
    Kozlov, Andrey
    Rudakova, Tatyana
    Klimova, Olesya
    Tcvetkov, Nikolai
    Pirogova, Olga
    Borzenkova, Evgeniya
    Kozhokar, Polina
    Ekushev, Kirill
    Paina, Olesya
    Bykova, Tatyana
    Darskaya, Elena
    Bondarenko, Sergey
    Zubarovskaya, Ludmila
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2018, 53 : 461 - 462
  • [26] Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study
    Liu, Jiapei
    Fan, Zhiping
    Xu, Na
    Ye, Jieyu
    Chen, Yanqiu
    Shao, Ruoyang
    Sun, Yiming
    Wu, Qiaoyuan
    Liu, Qifa
    Jin, Hua
    ANNALS OF HEMATOLOGY, 2023, 102 (10) : 2865 - 2877
  • [27] Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study
    Jiapei Liu
    Zhiping Fan
    Na Xu
    Jieyu Ye
    Yanqiu Chen
    Ruoyang Shao
    Yiming Sun
    Qiaoyuan Wu
    Qifa Liu
    Hua Jin
    Annals of Hematology, 2023, 102 : 2865 - 2877
  • [28] Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients With Steroid-refractory Acute GRAFT-VS-HOST Disease (SR-AGVHD): 6-Month Follow-up From The Randomized, Phase 3 Reach2 Study
    Mohty, Mohamad
    Bulabois, Claude-Eric
    Garcia-Gutierrez, Valentin
    Ritchie, David
    Yoon, Sung-Soo
    Coiteux, Valerie
    Kwong, Yok-Lam
    Niederwieser, Dietger
    Or, Reuven
    Socie, Gerard
    von Bubnoff, Nikolas
    Zeiser, Robert
    Xu, Judith
    Morando, Juliane
    Mahuzier, Bruyere
    Szer, Jeff
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 80 - 82
  • [29] Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study
    Socie, Gerard
    Xue, Zhenyi
    Bhatt, Valkal
    Galvin, John
    Mohty, Mohamad
    BLOOD, 2022, 140 : 4765 - 4766
  • [30] Ruxolitinib in Pediatric Patients with Treatment-Naive or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study
    Locatelli, Franco
    Kang, Hyoung Jin
    Bruno, Benedicte
    Gandemer, Virginie
    Rialland, Fanny
    Faraci, Maura
    Takahashi, Yoshiyuki
    Koh, Katsuyoshi
    Bittencourt, Henrique
    Cleary, Grace
    Rosko, Christine
    Roussou, Pantelia
    St Pierre, Annie
    Prahallad, Anirudh
    Diaz-de-Heredia, Cristina
    BLOOD, 2022, 140 : 1376 - 1378
12345